|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Researchers here tested the likelihood of distant cancer recurrence in breast cancer patients with no involved lymph nodes and estrogen-receptor-positive tumors. They used the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 genes (16 cancer related and 5 reference genes) in tumor tissue from each patient to prospectively define a “cancer recurrence score” and create a risk profile for each patient in the study.
“The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent respectively…In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size. The recurrence score was also predictive of overall survival…and could be used as a continuous function to predict distant recurrence in individual patients.”
|home spotlight commentary research events news about contact links archives|